1. EuroPCR25th annual meeting of theEuropean Association ofPercutaneous CardiovascularInterventions (EAPCI)Paris20-23 May 2014

2. EuroPCR 2014Paris20-23 May 2014Evolution of adjunctive antiplatelettherapy in non-urgent PCISupported by an unrestricted educational grant fromAstraZeneca 3. Date of preparation May 2014 BRI001132Disclaimer AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) andAstraZeneca Global Policies, and as such will not engage in the promotion ofunregistered products or unapproved indications. These highlights have been suggested by a group of cardiologists who attendedEuroPCR 2014, compiled by an external medical writer and sponsored byAstraZeneca. AstraZeneca has obtained permission from EuroPCR, to utilise the selected content foreducational purposes. Statements of fact and opinions expressed are those of the speakers individually and,unless expressly stated to the contrary, are not the opinion or position of AstraZeneca.AstraZeneca does not endorse or approve, and assumes no responsibility for, thecontent, accuracy, or completeness of the information presented. Presentations areintended for educational purposes only and do not replace independent professionaljudgement. Please refer to the appropriate approved Product Information before prescribing anyagents mentioned in these highlights.AstraZeneca Pty Ltd, Alma Road, North Ryde 2113 ABN: 54 009 682 311 4. EuroPCR 2014Paris20-23 May 2014 5. EuroPCR 2014Paris20-23 May 2014 6. EuroPCR 2014Paris20-23 May 2014 7. EuroPCR 2014Paris20-23 May 2014 8. EuroPCR 2014Paris20-23 May 2014 9. EuroPCR 2014Paris20-23 May 2014 10. EuroPCR 2014Paris20-23 May 2014 11. EuroPCR 2014Paris20-23 May 2014 12. EuroPCR 2014Paris20-23 May 2014 13. EuroPCR 2014Paris20-23 May 2014 14. EuroPCR 2014Paris20-23 May 2014 15. EuroPCR 2014Paris20-23 May 2014 16. EuroPCR 2014Paris20-23 May 2014 17. EuroPCR 2014Paris20-23 May 2014 18. EuroPCR 2014Paris20-23 May 2014 19. EuroPCR 2014Paris20-23 May 2014Ticagrelor is not indicated for use in patients with stable coronary artery disease. 20. EuroPCR 2014Paris20-23 May 2014 21. EuroPCR 2014Paris20-23 May 2014 22. EuroPCR 2014Paris20-23 May 2014 23. EuroPCR 2014Paris20-23 May 2014 24. EuroPCR 2014Paris20-23 May 2014Ticagrelor, in combination with aspirin is indicated for the prevention of atherothrombotic events in patients with ACS.Ticagrelor is not indicated in any patient populations other than in ACS. 25. EuroPCR 2014Paris20-23 May 2014Ticagrelor, in combination with aspirin is indicated for the prevention of atherothrombotic events in patients with ACS.Ticagrelor is not indicated in any patient populations other than in ACS. 26. EuroPCR 2014Paris20-23 May 2014Ticagrelor, in combination with aspirin is indicated for the prevention of atherothrombotic events in patients with ACS.Ticagrelor is not indicated in any patient populations other than in ACS. 27. EuroPCR 2014Paris20-23 May 2014Ticagrelor, in combination with aspirin is indicated for the prevention of atherothrombotic events in patients with ACS.Ticagrelor is not indicated in any patient populations other than in ACS.